NetraMark Holdings Inc. logo

NetraMark Holdings Inc. (AINMF)

Market Closed
7 Aug, 20:00
OTC PINK OTC PINK
$
0. 54
-0.06
-9.9015%
$
42.59M Market Cap
- P/E Ratio
- Div Yield
4,646 Volume
0 Eps
$ 0.6
Previous Close
Add Transaction
Day Range
0.53 0.54
Year Range
0.4 1.26
Want to track AINMF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

AINMF closed Friday lower at $0.54, a decrease of -9.9015% from Thursday's close, completing a monthly increase of 34.4496% or $0.14. Over the past 12 months, AINMF stock lost -32.1463%.
AINMF is not paying dividends to its shareholders.
The last earnings report, released on Jan 14, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on TSX (CAD).

AINMF Chart

NetraMark Holdings Inc. (AINMF) FAQ

What is the stock price today?

The current price is $0.54.

On which exchange is it traded?

NetraMark Holdings Inc. is listed on OTC PINK.

What is its stock symbol?

The ticker symbol is AINMF.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 42.59M.

Has NetraMark Holdings Inc. ever had a stock split?

No, there has never been a stock split.

NetraMark Holdings Inc. Profile

Insurance Industry
Financials Sector
Mr. George Achilleos CEO
OTC PINK Exchange
CA64119M1059 ISIN
Canada Country
- Employees
- Last Dividend
- Last Split
- IPO Date

Overview

NetraMark Holdings Inc. specializes in developing advanced artificial intelligence (AI) and machine learning (ML) solutions aimed at addressing unique challenges within the pharmaceutical industry in Canada. Formerly known as Nurosene Health Inc., the company underwent a rebranding to NetraMark Holdings Inc. in February 2023. Established in 2016, NetraMark has positioned itself as a trailblazer in leveraging technology to enhance healthcare outcomes. The company's headquarters are located in Toronto, Canada, where its team of experts focuses on innovating and improving the ways pharmaceutical data is analyzed and utilized for drug development and patient care.

Products and Services

  • NetraAI

An interactive augmented intelligence platform that integrates AI with human insights to optimize pharmaceutical research and development processes. NetraAI is designed to accelerate drug discovery and development, enhancing the efficiency of research studies and clinical trials through advanced data analytics.

  • Netra Shatter

This tool represents a breakthrough in data analysis, breaking down complex health datasets into understandable and actionable insights. Netra Shatter utilizes AI-driven algorithms to identify key patterns and correlations that can inform decision-making processes in drug development and personalized medicine.

  • Netra Health Atlas

A comprehensive digital repository of health data, the Netra Health Atlas facilitates an in-depth understanding of various health conditions and treatment outcomes. It serves as a valuable resource for researchers, clinicians, and pharmaceutical companies, offering access to a wealth of information that supports the advancement of medical knowledge and the development of more effective healthcare solutions.

Contact Information

Address: 1655 Dupont Street
Phone: 403-681-2549